ATE425966T1 - Durch phenyl subtituierten piperidinverbindungen zur verwendung als ppar-aktivatoren - Google Patents

Durch phenyl subtituierten piperidinverbindungen zur verwendung als ppar-aktivatoren

Info

Publication number
ATE425966T1
ATE425966T1 AT03811832T AT03811832T ATE425966T1 AT E425966 T1 ATE425966 T1 AT E425966T1 AT 03811832 T AT03811832 T AT 03811832T AT 03811832 T AT03811832 T AT 03811832T AT E425966 T1 ATE425966 T1 AT E425966T1
Authority
AT
Austria
Prior art keywords
subtituted
phenyl
piperidine compounds
ppar activators
ppar
Prior art date
Application number
AT03811832T
Other languages
German (de)
English (en)
Inventor
Scott William Bagley
Thomas Andrew Brandt
Robert Wayne Dugger
William Andrew Hada
Cheryl Myers Hayward
Zhengyu Liu
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE425966T1 publication Critical patent/ATE425966T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03811832T 2002-11-26 2003-11-14 Durch phenyl subtituierten piperidinverbindungen zur verwendung als ppar-aktivatoren ATE425966T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42950602P 2002-11-26 2002-11-26

Publications (1)

Publication Number Publication Date
ATE425966T1 true ATE425966T1 (de) 2009-04-15

Family

ID=32393563

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03811832T ATE425966T1 (de) 2002-11-26 2003-11-14 Durch phenyl subtituierten piperidinverbindungen zur verwendung als ppar-aktivatoren

Country Status (33)

Country Link
US (2) US7199243B2 (enExample)
EP (1) EP1567493B1 (enExample)
JP (1) JP4029091B2 (enExample)
KR (2) KR100760055B1 (enExample)
CN (1) CN100439337C (enExample)
AR (1) AR042131A1 (enExample)
AT (1) ATE425966T1 (enExample)
AU (1) AU2003276596B8 (enExample)
BR (1) BR0316521A (enExample)
CA (1) CA2507465C (enExample)
CO (1) CO5570701A2 (enExample)
DE (1) DE60326752D1 (enExample)
DK (1) DK1567493T3 (enExample)
EA (1) EA008928B1 (enExample)
ES (1) ES2321509T3 (enExample)
GT (1) GT200300258A (enExample)
HR (1) HRP20050437A2 (enExample)
IS (1) IS7816A (enExample)
MA (1) MA27532A1 (enExample)
MX (1) MXPA05005583A (enExample)
NL (1) NL1024881C2 (enExample)
NO (1) NO20052921L (enExample)
NZ (1) NZ539546A (enExample)
PE (1) PE20040699A1 (enExample)
PL (1) PL378268A1 (enExample)
PT (1) PT1567493E (enExample)
SI (1) SI1567493T1 (enExample)
TN (1) TNSN05146A1 (enExample)
TW (1) TW200424172A (enExample)
UA (1) UA83202C2 (enExample)
UY (1) UY28097A1 (enExample)
WO (1) WO2004048334A1 (enExample)
ZA (1) ZA200503104B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008928B1 (ru) * 2002-11-26 2007-08-31 Пфайзер Продактс Инк. Активаторы рецепторов, активируемых пролифератором пероксисом (ppar )
JP2008500328A (ja) * 2004-05-25 2008-01-10 ファイザー・プロダクツ・インク 新規な使用
WO2005115389A2 (en) * 2004-05-25 2005-12-08 Pfizer Products Inc. Specific ppar agonists for treating negative energy balance
BRPI0515015A (pt) * 2004-08-11 2008-07-01 Kyorin Seiyaku Kk derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
CN101189231B (zh) * 2005-03-23 2011-05-18 杏林制药株式会社 环状氨基苯基链烷酸衍生物
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
CN101296914B (zh) * 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
US9173875B2 (en) * 2006-04-11 2015-11-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists
EP2094685B1 (en) * 2006-12-01 2011-01-19 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors
EP2178534A4 (en) * 2007-07-17 2011-03-30 Merck Sharp & Dohme SOLUBLE EPOXYHYDROLASE HEMMER, COMPOSITIONS WITH SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
ES2551095T3 (es) * 2007-07-19 2015-11-16 Lundbeck, H., A/S Amidas heterocíclicas de 5 miembros y compuestos relacionados
TW201006816A (en) 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
FR2935510B1 (fr) 2008-08-28 2010-12-10 Oberthur Technologies Procede d'echange de donnees entre deux entites electroniques
FR2935511B1 (fr) 2008-08-28 2010-12-10 Oberthur Technologies Procede d'echange de donnees entre deux entites electroniques
UA107938C2 (en) * 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
WO2011037793A1 (en) * 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
TWI513695B (zh) * 2009-10-27 2015-12-21 Merck Sharp & Dohme （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物
EP2363825B1 (fr) 2010-03-04 2016-04-27 Inside Secure Procédé pour conduire une transaction au moyen d'un dispositif NFC
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
RU2615769C2 (ru) * 2015-07-29 2017-04-11 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Уфимский Государственный Университет Экономики И Сервиса" Средство для ингибирования фермента альфа-амилазы
US20220411372A1 (en) * 2019-09-20 2022-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small-molecule inhibitors for the b-catenin/b-cell lymphoma 9 protein-protein interaction
CN116162056A (zh) * 2021-11-24 2023-05-26 上海医药工业研究院 β-catenin/BCL9蛋白-蛋白相互作用的小分子抑制剂及其应用
WO2024022521A1 (zh) * 2022-07-28 2024-02-01 南通环聚泰生物科技有限公司 靶向BCL9/β-连环蛋白互相作用的小分子化合物
WO2024145931A1 (zh) * 2023-01-06 2024-07-11 上海医药工业研究院有限公司 β-catenin/BCL9蛋白蛋白相互作用的小分子抑制剂及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2025518A1 (enExample) * 1969-06-05 1970-12-10
US4476311A (en) * 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
EP0077607A1 (en) * 1981-09-17 1983-04-27 Beecham Group Plc N-substituted 3-aryl piperidines and derivatives thereof
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate
GB9027023D0 (en) * 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5274143A (en) * 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
AU2869092A (en) 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
WO1993012086A1 (fr) * 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Derive d'arylamide
JPH05255089A (ja) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JP3233991B2 (ja) * 1992-06-26 2001-12-04 株式会社ソフィア 遊技機
EP0607536B1 (en) * 1992-12-08 2001-01-24 Ss Pharmaceutical Co., Ltd. Arylamide derivatives
WO1996002250A1 (en) 1994-07-20 1996-02-01 Acea Pharmaceuticals Inc. Haloperidol analogs and the use thereof
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH09312086A (ja) * 1996-05-22 1997-12-02 Matsushita Electric Ind Co Ltd 光ディスク再生システム、光ディスク再生方法および光ディスク
WO1998005331A2 (en) 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
IT1286497B1 (it) * 1996-11-20 1998-07-15 Italfarmaco Sud Spa Difosfine di tipo misto eteroariliche-ariliche come leganti chirali, relativi complessi con metalli di transizione e impiego di detti
PL340958A1 (en) * 1997-12-19 2001-03-12 Merck & Co Inc Derivatives of aryl thiazolydinone
DK0952154T3 (da) * 1998-04-16 2004-12-13 Pfizer Prod Inc N-acyl- og N-aroylaralkylamider
US6376494B1 (en) * 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
CA2324330A1 (en) * 1999-11-08 2001-05-08 Ssp Co., Ltd. 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
AU2000258650A1 (en) 2000-05-11 2001-11-20 Eli Lilly And Co 2-piperidone compounds for the treatment of cancer
AU2001257413B2 (en) 2000-05-22 2007-01-18 Aventisub Llc Arylmethylamine derivatives for use as tryptase inhibitors
WO2002028834A1 (en) 2000-10-06 2002-04-11 Smithkline Beecham P.L.C. Process for the preparation of aryl-piperidine carbinols and intermediates thereof
CN1469862A (zh) 2000-10-12 2004-01-21 Ss制药株式会社 2,2-二苯基丁酰胺衍生物和含有它的药物
JP2002173426A (ja) 2000-12-05 2002-06-21 Ss Pharmaceut Co Ltd 血糖低下剤
WO2002064549A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
JP2004523543A (ja) * 2001-02-15 2004-08-05 ニューロサーチ、アクティーゼルスカブ 神経栄養活性を有する化合物とドパミン活性を増加させる化合物の組み合わせ作用によるパーキンソン病の治療法
EA008928B1 (ru) * 2002-11-26 2007-08-31 Пфайзер Продактс Инк. Активаторы рецепторов, активируемых пролифератором пероксисом (ppar )

Also Published As

Publication number Publication date
DK1567493T3 (da) 2009-06-08
CA2507465C (en) 2009-04-28
NO20052921L (no) 2005-08-18
KR20050086794A (ko) 2005-08-30
US20040157885A1 (en) 2004-08-12
EA200500629A1 (ru) 2005-12-29
KR20070063051A (ko) 2007-06-18
JP2006509001A (ja) 2006-03-16
GT200300258A (es) 2004-11-30
ZA200503104B (en) 2006-12-27
EP1567493A1 (en) 2005-08-31
CO5570701A2 (es) 2005-10-31
NZ539546A (en) 2007-11-30
HK1083502A1 (zh) 2006-07-07
NO20052921D0 (no) 2005-06-15
CN100439337C (zh) 2008-12-03
US7199243B2 (en) 2007-04-03
HRP20050437A2 (en) 2005-10-31
KR100760055B1 (ko) 2007-09-18
AU2003276596A1 (en) 2004-06-18
US20070191429A1 (en) 2007-08-16
UY28097A1 (es) 2004-06-30
TNSN05146A1 (fr) 2007-05-14
PL378268A1 (pl) 2006-03-20
CN1717389A (zh) 2006-01-04
SI1567493T1 (sl) 2009-06-30
KR100875318B1 (ko) 2008-12-22
WO2004048334A1 (en) 2004-06-10
EA008928B1 (ru) 2007-08-31
CA2507465A1 (en) 2004-06-10
MXPA05005583A (es) 2005-07-27
IS7816A (is) 2005-04-20
NL1024881A1 (nl) 2004-05-27
UA83202C2 (ru) 2008-06-25
NL1024881C2 (nl) 2009-09-16
BR0316521A (pt) 2005-10-04
AR042131A1 (es) 2005-06-08
ES2321509T3 (es) 2009-06-08
DE60326752D1 (de) 2009-04-30
EP1567493B1 (en) 2009-03-18
MA27532A1 (fr) 2005-09-01
AU2003276596B2 (en) 2009-02-12
PE20040699A1 (es) 2004-10-23
TW200424172A (en) 2004-11-16
PT1567493E (pt) 2009-04-09
AU2003276596B8 (en) 2009-03-05
JP4029091B2 (ja) 2008-01-09

Similar Documents

Publication Publication Date Title
ATE425966T1 (de) Durch phenyl subtituierten piperidinverbindungen zur verwendung als ppar-aktivatoren
DE60115937D1 (de) Piperidinverbindungen zur verwendung als antiallergika
ATE430147T1 (de) Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf)
ATE447553T1 (de) Piperidinverbindungen zur verwendung als ccr-3- inhibitoren
SE0302305D0 (sv) Novel Compounds
ECSP066436A (es) Compuestos heterociclicos fusionados
IS7879A (is) Ný efnasambönd
DE60322030D1 (de) Lichtempfindliches element zur benutzung als flexodruckplatte
FI20030030A0 (fi) Uusia yhdisteitä
ATE461175T1 (de) Neue piperidinverbindungen
IS7827A (is) Ný efnasambönd
ATE425169T1 (de) Heterotricyclyl-6-alkylidenpeneme als beta- lactamaseinhibitoren
IS8292A (is) Ný efnasambönd
DE50311406D1 (de) Verwendung von Formkörpern
DE60210254D1 (de) Aminosubstituierter hypocrelline zur verwendung als sonosensitizer
ATE390413T1 (de) 4-(2-phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridinderivaten zur verwendung als serotonin-wiederaufnahmehemmer
ATE455770T1 (de) N-alkynyl-2-heteroaryloxyalkylamide zur verwendung als fungizide
DE602006007549D1 (de) Verwendung von morpholino-verbindungen zur verhinderung bakteriellen befalls
DE602004031355D1 (de) Neue 1,3-disubstituierte azetidinderivate zur verwendung als liganden des 5ht2a-rezeptors
ATE394140T1 (de) Verwendung neuer etonogestrelester
SE0303452D0 (sv) New compounds
ATE500220T1 (de) 2-(1h-indolylsulfanyl)benzylamin-derivate zur verwendung als ssri
ATA8672002A (de) Spindelantriebskupplung
ATE321571T1 (de) Aminosubstituierter hypocrelline zur verwendung als sonosensitizer
DE60304811D1 (de) Toner zur Verwendung in nahezu licht-unempfindlichen Aufzeichnungsmaterialien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1567493

Country of ref document: EP

REN Ceased due to non-payment of the annual fee